Common IBD Meds Acquitted in Severe COVID Outcomes
Both biologics and mesalamine/sulfasalazine were not linked to severe COVID-19 outcomes in inflammatory bowel disease (IBD) patients, according to findings from the ongoing global SECURE-IBD trial. There was no association between mesalamine/sulfasalazine and adverse COVID outcomes. And when examining biologic-treated patients, there was no link between mesalamine/sulfasalazine use and either severe COVID-19 (adjusted odds ratio […]